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ABSTRACT 
Background: Outbreaks of meningococcal disease are infrequent but important 
public health events. Epidemiological characteristics of outbreak-associated cases 
compared with sporadic disease are not well described. 
Methods: Outbreaks of meningococcal disease from 7/1/94-6/30/02 were 
identified through state health departments, CDC records, and newspaper and 
medical literature review. An outbreak was defined as three primary patients with 
meningococcal disease caused by the same serogroup within 3 months in a 
community, or two patients in an institution, resulting in an attack rate of 
2:10/100,000 population. Cases associated with outbreaks were compared with 
sporadic cases identified through population-based surveillance. 
Results: We identified 76 outbreaks over the 8-year period of the study, which 
gave a median of 10 outbreaks per year (annual median= 10, range 4-16) involving 
a total of247 patients (annual median=30, range 8-92) from 32 states. Forty-eight 
(63%) of the outbreaks were serogroup C, 19 (25%) were serogroup B, and 9 
(12%) were serogroup Y. Twenty-six (34%) outbreaks occurred in communities, 
representing 53% of cases; 50 (66%) outbreaks were institution-based, including 
13 colleges and universities, 19 primary and secondary schools, and 9 nursing 
homes. Vaccination campaigns (NC/Y/W-135 meningococcal polysaccharide 
vaccine) were conducted in 34 outbreaks (30 serogroup C, 4 serogroup Y) 
utilizing 2,500 doses/outbreak. After controlling for age, serogroup, and clinical 
presentation, outbreak-associated cases had a higher case-fatality rate than 
sporadic cases [21% vs. 11%, Odds Ratio (OR) 2.1, 95% confidence interval (CI) 
1.4-3.1]. 
Conclusions: Certain clones of N. meningitidis with genetic factors that favor 
their transmission and increase their virulence may be responsible for most 
outbreaks, resulting in higher case fatality rates for outbreaks compared to 









Neisseria meningitidis is a gram negative diplococcus capable of causing 
several clinical syndromes including meningitis, bacteremia accompanied by 
sepsis and rash, and pneumonia.1 At any given time, N meningitidis is found 
living in about 5-10% of the general population's nasopharynx. 1 Most individuals 
living in the United States carry non-pathogenic strains of the bacteria and will 
! 
not develop disease; even those carrying pathogenic strains usually do not become 
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ill. 1 Transmission occurs between humans through direct contact with respiratory i 
secretions from a nasopharyngeal carrier. 2 
Infection with N meningitidis is a serious and potentially fatal disease. In 
patients from whom N meningitidis is isolated from their cerebrospinal fluid, 
about 13% will die; roughly 11.5% of persons who haveN meningitidis isolated 
from their blood will die.3 Among patients who recover, 10-15% will have 
serious sequelae, such as permanent hearing loss, mental retardation, or loss of 
limbs.2 While meningococcal disease is responsive to antibiotic therapy, 
potentially reducing the risk of dying to below 15%,2 it is important to start 
treatment as early in the course of disease as possible since symptoms can 
progress rapidly over the course of just a few hours. 
Overall, an estimated 2,400 to 2,600 cases of meningococcal disease occur 
in the United States each year (approximately 1.1 cases/1 00,000 population).34 
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Studies have shown that the frequency of meningococcal disease outbreaks in the 
U.S. increased during the first half of the 1990s.5-6 Both outbreak-associated and 
sporadic meningococcal disease occur in the U.S.; however, only 2% of cases are 
associated with outbreaks. 5 Infants and young children are at highest risk for 
invasive disease/ and other studies have shown that college freshmen living in 
dormitories are at elevated risk of disease compared to the general population. s-9 
Characterized by antigenic differences in their polysaccharide capsules, 
four different serogroups of N. meningitidis cause the majority of disease in the 
United States: C, B, Y, and W -135. 1 Serogroup A disease, which is endemic in 
Africa, largely disappeared from the United States during the 1970s and 1980s.1 
Between 1989 and 1991,46% of cases were caused by serogroup B, 45% by 
serogroup C, 3% by serogroup W-135, and 2% by serogroup Y10 However, 
surveillance between 1992 and 1996 found that the serogroup distribution had 
changed: 35% of cases were caused by serogroup C, 32% by serogroup B, and 
26% by serogroup Y.4 Reasons for the changing serogroup distribution are l 
unclear. 
A quadrivalent vaccine consisting of purified bacterial capsular 
polysaccharides from serogroups A, C, Y, and W -135 is currently available for 
the prevention of meningococcal disease in the United States.3 The usefulness of 
the vaccine is limited, however, due to its relative ineffectiveness in children 
under 2 years of age and its short duration of protection. Antibody production 
induced by serogroup A polysaccharide occurs in some children as young as 3 
months of age; however, responses comparable to those of adults do not occur 
until4 or 5 years of age. Recipients of serogroup C vaccine less than 18 to 24 
months of age do not form an adequate immune response to confer protection 
against infection. In those persons who do mount an adequate immune response 
to vaccination with serogroup A and C polysaccharides, measurable levels of 
antibodies fall appreciably during the first three years after inoculation, especially 
in infants and children. Polysaccharides from serogroups Y and W-135 are 
sufficiently immunogenic and safe only in persons over 2 years of age.3 
Polysaccharides for serogroup B are not included in the vaccine because these 
polysaccharides fail to induce immunity, even in adults. 11 
Due to the limitations of the currently available polysaccharide vaccine 
and the rarity of meningococcal disease, routine vaccination of the general 
population is not recommended. Use of the vaccine is limited to persons traveling 
to countries with hyperendemic or epidemic meningococcal disease, high-risk 
groups (e.g. military personnel and immunodeficient persons), and to prevent the 
spread of vaccine-preventable disease during outbreaks.3 
Given that 60% of cases of meningococcal disease are caused by 
serogroups covered in the currently licensed vaccine and are thus preventable,4 it 
is important that surveillance of this disease be continued. This study seeks to 
describe meningococcal disease occurring in the United States between 1994 and 
2002, comparing clusters of outbreak disease with more common sporadic cases. 
Additionally, the specificity of the threshold for detecting outbreaks of 
meningococcal disease-established by current ACIP guidelines-will be 
assessed. 
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A confirmed case of meningococcal disease was defined by isolation of N. 
meningitidis from a normally sterile site in a person with clinically compatible 
illness. All isolates were serogrouped. A meningococcal cluster was loosely 
defined as 2 or more patients with probable meningococcal disease who were 
associated by time and place and resulted in an increased attack rate compared 
with that usually observed in a defined population. We then classified clusters 
according to the population affected. The cluster was institutional if all of the 
case patients had a common affiliation with that institution (e.g. students at a 
school, residents in a nursing home) or were household contacts of persons 
affiliated with the institution. If no single institutional affiliation was identified, 
the cluster was classified as community-based. 
In accordance with the ACIP guidelines, we defined an institutional 
outbreak of meningococcal disease as the occurrence of two or more confirmed 
cases of meningococcal disease of the same serogroup during a period of three 
months in persons with a common affiliation, but no close contact with each 
other, resulting in an attack rate of at least 10 per 100,000 population. We 
defined a community-based outbreak as the occurrence ofthree or more 
confirmed cases of the same serogroup during a period of three months among 
persons who resided in the same geographic area, but who were not close 









least 10 per 100,000 population. Most frequently, county lines were used to 
determine denominators for calculation of community attack rates; however, city, 
town, zip codes, etc. were used when appropriate. 
Clinical syndromes, including meningitis, meningococcemia, and 
pneumonia, were assigned by clinicians at the time of presentation and were 
subsequently reported by state health departments. 
Data Collection 
Data on clusters of meningococcal disease cases occurring between July 
I, 1994 and June 30,2002 were first obtained by searching a log of 
meningococcal disease cases maintained by the Centers for Disease Control and 
Prevention (CDC). The purpose of this log is to maintain communication 
between the CDC and public health officials in the community so that the CDC 
can be aware of possible ongoing meningococcal outbreaks and give guidance 
about the need for starting a vaccination campaign or initiating a more in-depth 
epidemiological investigation. Outside of this log there is no systematic 
surveillance for clusters of meningococcal disease. To supplement the CDC 
records, reports from each state health department were requested for all cases of 
meningococcal disease clustered in time and geographic location. Data for cases 
that may not have been reported to state health departments or included in CDC 
records were obtained by searching MEDLINE and Lexis-Nexis Academic for 
case reports or media reports of cases. Indexing terms for MEDLlNE included 








meningitis," and "disease outbreaks." In Lexis-Nexis Academic, a Guided News 
Search was performed within the category "U.S. News" in the sections "Midwest 
Regional News," "Northeast Regional News," "Southeast Regional News," and 
"Western Regional News" using the truncated term "meningococ!" in the full text 
and limited to 1997 to 2002. The results of the Medline and Lexis-Nexis 
Academic searches were also used to fill in any missing data from cases and 
clusters provided by the state and territorial health departments. All clusters ' 
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were confirmed with the state health department. 
Data on sporadic meningococcal disease for comparison to outbreak-
associated cases and for evaluation of the specificity ofthe threshold were 
obtained from the Active Bacterial Core Surveillance Group (ABCs ), an active, 
population-based CDC surveillance system conducted throughout the course of 
the study among an aggregate population of33.3 million. It consists of all 
residents from three counties in California (Alameda, Contra Costa, San L 
Francisco), five counties in Colorado (Adams, Arapahoe, Denver, Douglas, 
Jefferson), fifteen counties in New York (Albany, Columbia, Genesee, Greene, 
Livingston, Monroe, Montgomery, Ontario, Orleans, Rennseiaer, Saratoga, 
Schenectady, Schoharie, Wayne, Yates), seven counties in Tennessee (Davidson, 
Hamilton, Knox, Rutherford, Shelby, Sumner, Williamson), and the states of 
Connecticut, Georgia, Maryland, and Minnesota. 
Threshold Evaluation 
We searched the active, population-based database from the ABCs for 
clusters in which at least 3 cases occurred within a 3-month time period in the 
counties under surveillance. We then calculated attack rates for those clusters 
using the denominators provided by the surveillance group. As the gold standard 
for a meningococcal outbreak, we used the ongoing surveillance for outbreaks 
declared by state health departments. 
Statistical Analysis 
For analyses comparing characteristics of outbreak -associated cases, 
categorical data were dichotomized and risk ratios (RRs) with 95% confidence 
intervals (Cis) were calculated. Patients were divided into seven age groups 
based on common characteristics of social interaction: <1 year, 1-5 years, 6-17 j__ 
years, 18-24 years, 25-39 years, 40-64 years, and :>:65 years. For bivariable 
analyses comparing outbreak-associated disease to sporadic disease, we 
calculated RRs with 95~0 Cis. Con1parisons of1nedians ¥.rere 1nade using 
Wilcoxon's ranked sum test. An adjusted analysis for risk of death for outbreak-
associated disease vs. sporadic disease was performed using logistic regression. 
The formal model included potential confounding variables and covariates 
associated with death with p<O.l on bivariable analysis. All statistical analyses 
were performed using STATA (version 7.0, College Station, TX). 
RESULTS 
Active surveillance with participation from all 50 states identified 190 
clusters (3,087 cases) of meningococcal disease from 43 states that occurred, at 
least in part, between July 1, 1994 and June 30, 2002. Seventy-six of the clusters 
involving 247 patients from 32 states met the definition for either a community-
based or institutional outbreak, which gave a median of 10 cases per year (range 
4-16) and a median of30 cases per year (range 8-92), (Fig.1). Forty-eight (63%) 
of the outbreaks were serogroup C, 19 (25%) were serogroup B, and 9 (12%) 
were serogroup Y. No outbreaks of serogroup A, W-135, or any other serogroup 
occurred in the time period of interest. Outbreaks showed a seasonal distribution 
similar to that of sporadic cases, with most cases occurring in late winter to early 
spnng. Outbreak cases accounted for <2% of total cases of invasive 
meningococcal disease each year. Table I shows characteristics of outbreak-
associated cases, stratified by serogroup. 
While only 26 (34%) of the outbreaks were community-based, they 
represented 53% of cases. Nineteen were serogroup C, 6 were serogroup B, and 
1 was serogroup Y. The median number of cases in community-based outbreaks 
was 4 (range 3-30) with 12 of26 having the minimum of3 cases. The other 50 
outbreaks (65%) were institution-based, including nineteen (38%) that occurred 
in primary and secondary schools, 13 (26%) in colleges and universities, and 9 
(18%) in nursing homes. Other sites of institutional outbreaks included hotels 
(2), a camp (1), a prison (1), a bar (1), a daycare (1), and a church (1). Twenty-
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nine institutional outbreaks were serogroup C, 13 were serogroup B, and 8 were 
serogroup Y. The median number of cases in institutional outbreaks was 2 (range 
2-5) with 30 of 50 having the minimum of2 cases. 
Clinical Presentation 
Most cases of outbreak -associated disease presented as meningitis, 
meningococcemia, pneumonia, or some combination of these syndromes. Of the 
228 cases (92% of total) for which the clinical syndrome was available, 54% 
presented with meningitis, 55% with meningococcemia, and 5% with pneumonia 
(cases may have been diagnosed with more than one clinical syndrome). Other i 
i less common clinical syndromes included pericarditis, endocarditis, rash, and sudden death. 
Clinical presentation varied with the patient's gender and the serogroup 
causing the infection. Men were more likely to present with meningitis than 
women (63% vs. 47%; RR 1.3, 95% CI 1.0-1.7), and cases ofserogroup C 
outbreak disease were more likely to present with meningitis than cases of non-
serogroup C disease (60% vs. 41 %; RR 1.5, 95% CI 1.1-2.0). 
Few differences in clinical syndrome were noted among the different age 
groups; however, patients 65 years or older were less likely to present with 
meningitis than patients in other age groups (20% vs. 57%; RR 0.4, 95% CI 0.1-
0.8). Additionally, all cases of pneumonia (n=ll) occurred among patients 65 
years or older. 
Outbreak vs. Sporadic Disease 
Serogroup and gender distribution differed between outbreak and 
sporadic disease (Table 2). A greater fraction of outbreak-associated cases than 
sporadic cases were serogroup C (67% vs. 29%; RR2.3, 95% CI 2.1-2.6), 
whereas a smaller percentage of outbreak -associated cases than sporadic cases 
were serogroup B (23% vs. 37%; RR 0.6, 95% CI 0.5-0.8) or serogroup Y (9% vs. 
32%; RR 0.3, 95% CI 0.2-0.4). While 59% of outbreak-associated cases occurred 
among males, only 51% of sporadic cases occurred among males (RR 1.2, 95% 
CI 1.0-1.3). 
Outbreak -associated cases and sporadic cases also demonstrated different 
age distributions. Similar percentages of children 1-5 years old were infected in 
outbreak and sporadic cases (20% vs. 16%; RR 1.3, 95% CI 1.0-1.6). However, a 
smaller percentage of children under 1 year of age were infected in outbreaks 
than in sporadic cases (3% vs. 14%; RR 0.2, 95% CI 0.1-0.5), as were adults 25-
39 years old (5% vs. 9%; RR 0.5, 95% CI 0.3-0.9), 40-64 years old (4% vs. 16%; 
RR 0.3, 95% CI 0.2-0.5), and 65 years or older (8% vs. 13%; RR 0.6, 95% CI 0.4-
1.0). A greater percentage of children between the ages of 6 and 17 were infected 
in outbreaks than in sporadic cases (37% vs. 20%; RR 1.9, 95% CI 1.6-2.3), as 
were patients between 18 and 24 years of age (22% vs. 12%; RR 1.8, 95% CI 1.4-
2.3). Median age for community outbreak-associated cases was 10 years, which 







Similar rates of meningitis were seen in outbreak-associated cases and 
sporadic cases (54% vs. 48%; RR 1.1, 95% CI 1.0-1.3). Pneumonia rates, 
however, differed between outbreak-associated cases (5%) and sporadic cases 
(9%), (RR 0.5, 95% CI 0.3-1.0). Data for clinical meningococcemia was not 
available for sporadic disease. 
Case-Fatality 
The overall case-fatality rate for the 224 outbreak-associated cases with 
available outcome data (91% of total) was 21%, regardless of whether cases were 
community-associated or institution-associated. This was greater than the overall 
case-fatality rate for sporadic cases (11 %), (RR 1.9, 95% CI 1.4-2.5), (Table 2). 
Case fatality did not differ for the initial case in an outbreak compared to later 
cases (23% vs. 20%; RR 1.2, 95% CI 0.7-2.0). 
There was no difference in case-fatality rate for community-associated 
outbreak cases as compared to institutional outbreak cases (20% vs. 22%; RR 
1.1, 95% CI 0. 7-1.8). Considering only outbreak-associated cases, case-fatality 
rates did not vary among serogroups (serogroup C 22%, serogroup B 18%, and 
serogroup Y 22%), nor according to age group. Outbreak-associated cases that 
presented with meningococcemia were more likely to die than outbreak-
associated cases presenting with other syndromes (31% vs. 10%; RR 3.2, 95% CI 
1.6-6.2). 
Case-fatality among serogroup C outbreak-associated cases was greater 
than that ofserogroup C sporadic cases (22% vs. 13%; RR 1.7, 95% CI 1.2-2.4) 
l 
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(Table 3). However, case-fatality was not greater among serogroup B outbreak 
cases than serogroup B sporadic cases (18% vs. 9%; RR 1.9, 95% CI 1.0-3.6), 
nor for serogroup Y outbreak cases compared to serogroup Y sporadic cases 
(22% vs. 11 %; RR 2.0, 95% CI 0.8-4.8). 
Case-fatality rates differed between outbreak-associated cases and 
sporadic cases, according to age group (Table 3). Outbreak-associated cases 
among patients aged 1-5 were more likely to die than sporadic cases among 
L 
patients of the same age group (24% vs. 5%; RR 4.8, 95% CI 2.5-9.3). Cases 
aged 6-17 that were associated with outbreaks were also more likely to die than 
sporadic cases aged 6-17 (20% vs. 9%; RR 2.2, 95% CI 1.3-3.6). Case-fatality 
rates did not differ between outbreak-associated cases and sporadic cases for 
other age groups. Overall, the median age of sporadic cases that had a fatal 
outcome (31.3 years, interquartile range (IQR) 16.1-62.1) was greater than the 
median age of community-associated outbreak cases that had a fatal outcome 
(10.0 years, IQR 5.0-19.0), (Wilcoxon ranked sum, p<O.OOOl). Comparing L 
outbreak-associated cases and sporadic cases, there were no differences in case-
fatality rates according to clinical syndrome. 
An adjusted analysis comparing the case-fatality rate for outbreak-
associated cases with that for sporadic cases and controlling for clinical 
presentation, age group, and serogroup found that the case-fatality rate was still 
higher among outbreak-associated cases than among sporadic cases (adjusted 
OR2.1, 95% CI 1.4-3.1). 
i--
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Temporal Aspects of Outbreaks 
Table 4 demonstrates tbe progression of meningococcal disease outbreaks 
over time by setting and serogroup. Median duration of community-associated 
outbreaks (42 days, IQR 22-88 days) was longer than that of institutional 
outbreaks (12 days, IQR 4-42 days), (Wilcoxon ranked sum, p=0.001). Most 
cases associated with institutional outbreaks occurred during the first week, 
whereas community-associated outbreaks were more prolonged. Institutional 
L 
outbreaks were significantly more likely to last less than 2 weeks compared to 
community-associated outbreaks (52% vs. 19%; OR 2.7, 95% CI 1.2-6.2). 
Median duration was equal for outbreaks of different serogroups (Wilcoxon 
ranked sum, p=0.8). Serogroup C outbreaks had a median duration of23 days, 
serogroup B of25 days, and serogroup Y of26 days. Additionally, 75% of 
serogroup C andY outbreaks lasted fewer than 2 months, while 75% of serogroup 
B outbreaks lasted fewer than 3 months. 
Vaccination Campaigns 
Of the 76 reported outbreaks of meningococcal disease, 57 were 
serogroup C or Y, for which vaccination campaigns were considered. 
Vaccination campaigns were implemented in 34 outbreaks, resulting in the use of 
over 190,000 vaccine doses at an estimated cost of over $14.4 million (Table 3). 
Threshold Evaluation 
We reviewed all meningococcal cases identified through the ABC surveillance 
sites and identified 149 clusters of at least 3 cases in 3 months in a single county 
that occurred between June 30, 1994 and July 1, 2002. Using county populations 
as denominators, 3 of the clusters met the outbreak definition by having an attack 
rate of2:1 0/100,000 population. All three clusters were serogroup B and were 
located in Oregon. No outbreaks were identified by the state health departments 
in the surveillance area over this time period. 
DISCUSSION 
Active surveillance of all 50 states identified 76 outbreaks of . 
meningococcal disease, representing 247 cases. Outbreaks of Neisseria ~-
meningitidis are still rare in the United States, comprising <2% of all cases. 
Historically, both outbreak-associated disease and sporadic disease have been 
most frequently associated with serogroup C N meningitidis.6 In the current 
study, serogroup distribution of outbreak-associated cases differed from that of 
sporadic cases, with outbreak-associated cases dominated by serogroup C 
disease, and sporadic cases dominated by serogroup B or serogroup Y disease. 
The most recent survey of sporadic meningococcal disease in the U.S. from 1992-
1996 found that serogroup C disease accounted for 35% of cases, serogroup B 
disease 32%, and serogroup Y disease 26%.4 In the current survey, the fraction of 
sporadic cases caused by serogroup C disease dropped to 29%, while the fraction 
of sporadic disease caused by serogroup B increased to 37% and serogroup Y 
increased to 32%. 
During the eight-year time period covered by this survey, outbreaks were 
reported in 32 ofthe 50 states (Fig. 1 ). Outbreaks had a broad geographical 
distribution, with many outbreaks occurring in eastern Texas and central Florida. 
The reason for these areas of concentration is not clear, but would seem to 
suggest the introduction of more virulent clones into particularly susceptible and 
immunologically na1ve populations. 
Community-associated outbreaks were found to be longer in duration than 
institutional outbreaks; however, this finding is likely to be an artifact of the 
different definitions of community- and institution-associated outbreaks. 
Community-associated outbreaks had to include 3 cases within a 3 month time 
period, whereas institutional outbreaks only had to include 2 cases. If only the 
first 2 cases in community-associated outbreaks with 3 cases were used to define 
the duration of the outbreak, then median duration of community-associated 
outbreaks dropped from 42 days to 31.5 days (IQR 11-88 days). This duration 
was still longer than institution-based outbreaks, but not nearly as significantly 
(p=0.04). 
The greatest number of cases of outbreak-associated disease occurred in 
children aged 6-17, closely followed by adults aged 18-24 and children aged 1-5. 
Compared to sporadic disease, outbreaks were significantly more likely to occur 






similar findings for serogroup C outbreak-associated disease compared to 
serogroup C sporadic disease.6 Such differences in age distribution for outbreak-
associated cases compared to sporadic cases are not surprising, given that many 
people in these age groups are in primary or secondary school or college. Living 
or even spending much time in such close quarters increases the ease and speed 
with which infections are spread, and thus makes these individuals more likely to 
contract meningococcal disease. Previous studies have shown that college 
students living on campus are at increased risk of contracting meningococcal 
disease. 8-9 Harrison et a!. also noted an increased frequency of meningococcal 
disease among Maryland residents aged 15-24 during the first part of the 1990s.12 
Gender distribution was also found to be different for outbreak -associated 
cases compared to sporadic cases. Cases of sporadic disease were virtually 
evenly split between men and women. However, among outbreak-associated 
cases, more men than women were affected. Socialization patterns that increase 
risk for contracting outbreak-associated meningococcal disease (e.g. smoking) 
may be more common among men than among women and thus be responsible for 
these differences. 
In the current study, case-fatality rates for outbreak-associated disease 
were found to be significantly higher than case-fatality rates for sporadic disease; 
outbreak -associated cases were ahnost twice as likely to die as sporadic cases, 
even after adjusting for age group, clinical syndrome, and serogroup. Prior 
studies have reported similar associations between age, clinical syndrome, and 
serogroup and increased case-fatality rates for sporadic disease.4 It is possible 
that certain clones of N meningitidis with genetic factors that favor their 
transmission and increase their virulence are responsible for most outbreaks. A 
high degree of genetic relatedness among strains of serogroup C bacteria causing 
outbreaks has been reported previously;6 however, analyses of sporadic disease 
have not found an association between specific enzyme types and increased case-
fatality rates.4 
Multilocus enzyme electrophoresis (MEE) has historically been the 
principal means of distinguishing different strains of N meningitidis from one 
another; however, with the development of pulsed field gel electrophoresis 
(PFGE) and polymerase chain reaction (PCR) techniques, MEE has fallen out of 
favor. Due to the current lack of agreement on a standard technique for 
determining bacterial strains, the current study was unable to collect data on 
strains of N meningitidis implicated in the outbreaks. Once guidelines for strain 
typing are established, however, studies will be able to better examine the 
relationships between outbreaks and particular strains of N meningitidis. 
Host factors that make certain persons more susceptible to catching 
disease and dying from it may also contribute to the increased fatality rate found 
among outbreak-associated cases. Another possible explanation is the existence 
of an ascertainment bias--cases that have a fatal outcome are more likely to be 
noticed by public health departments and thus the outbreaks related to them are 
more likely to be reported. However, if such a bias existed, the frequency of death 
among initial cases in outbreaks would be higher than that among later cases. In 
the current study, however, initial cases were equally as likely to die as later 
cases. 
The importance and legitimacy of comparisons of clinical presentation are 
difficult to assess given the inherently vague and subjective way in which clinical 
presentation was defined. Given that many of the signs and symptoms used to 
make these diagnoses are non-specific, there is a good possibility that some 
patients were incorrectly diagnosed, especially iflaboratory cultures were not 
drawn to back up clinical findings. Furthermore, differences seen between 
patients presenting with meningitis and those presenting with meningococcemia 
are suspect since patients with meningitis are presumed to have been bacteremic 
at some point during the course of disease. Of course, bacteremia does not 
inevitably lead to meningococcemia, so it is possible for patients to have 
meningitis but not meningococcemia. 
With these caveats in mind, however, distinct patterns of clinical 
syndromes were noted among outbreak-associated cases. Men were more likely 
to present with meningitis, while women were more likely to be diagnosed with 
meningococcemia or pneumonia. Given that cases presenting with 
meningococcemia were found to be at higher risk for death, it was expected that 
women would be at greater risk of death; however, this expectation did not 
hold~men and women were found to be equally at risk of death. All outbreak-
associated cases of pneumonia occurred among individuals over 65 years of age; 
furthermore, 80% of those over 65 were women. This explains in part why 
women were more likely to get pneumonia than men. Other reasons for why 
clinical syndrome would vary with gender are unclear. Such findings seem more 
likely to be due to biases in the clinical care that men and women receive (and 
thus differences in received tests and diagnoses) than in physiologic differences 
between the two sexes. 
Clinical presentation among outbreak-associated cases was also found to 
vary according to serogroup, with serogroup C cases more frequently presenting 
as meningitis and serogroup Y cases more frequently presenting as 
meningococcemia or pneumonia. These differences may be ascribed to 
differences in bacterial characteristics among the different serogroups of N 
meningitidis. Different serogroups may harbor "trophic" factors that direct them 
to different areas of the body. For example, serogroup C bacteria may have 
genetic factors that enable them to preferentially inhabit the CSF while serogroup 
Ybacteria may have ones that enable them to preferentially survive in the blood 
or lungs. The association of serogroup Y disease with pneumonia has been 
previously reported. 4 Alternatively, these differences may again be explained by 
biased assessments and diagnoses made by clinicians. 
Rates of pneumonia were found to be higher among sporadic cases than 
among outbreak-associated cases. This is likely due to the fact that serogroup Y 
N meningitidis, the primary cause of meningococcal pneumonia, was much more 
common in sporadic disease than outbreak -associated disease. 
Upon reviewing the ABC surveillance data for evaluating the threshold 
definition for outbreaks, we found 3 clusters of serogroup B disease in Oregon 
that met our outbreak definition. Interestingly, while Oregon has been 
experiencing hyperendemic serogroup B disease in recent years (CDC, 
unpublished data), the state health department did not report any clusters that 
met our definitions of outbreak disease. However, the current ACIP definition 
was primarily created to detect outbreaks of serogroup C disease in an effort to 
establish guidelines for when to implement vaccination campaigns and prevent 
the further spread of disease. Since serogroup B disease is not preventable with 
the current vaccine, there was no need for the state health department in Oregon 
to declare these clusters to be outbreaks once they reached an attack rate over 
10/100,000 population. The fact that no other clusters of cases among the ABCs 
data met the outbreak definition and no outbreaks were identified by state health 
departments suggests that the specificity of the current threshold is high. It is 
thus unlikely that vaccination campaigns are being initiated unnecessarily. 
Current ACIP guidelines recommend initiating vaccine campaigns for 
situations in which 3 or more cases of meningococcal disease have been identified 
in a community or institution in :S3 months and the primary attack rate is 
2::10/100,000 population. In institutional settings, however, the occurrence of 
even 2 cases in a such a short time-period may warrant consideration of a 
vaccination campaign, given the rarity of meningococcal disease and thus the 
unlikely circumstance that the two cases are unrelated. The appropriateness of 
this outbreak definition and prompt assessment of potential outbreaks are 
important public health issues given the high morbidity and mortality associated 
with meningococcal disease, as well as the high expense associated with 
launching vaccination campaigns. As highlighted in this survey, case-fatality is 
likely to be even higher in outbreaks. Given the current ACIP guidelines' high 
threshold for detecting meningococcal outbreaks, we recommend their continued 
use for assessing potential outbreaks and for deciding the appropriate time to 
implement prophylaxis and vaccination campaigns. 
l 
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Fig. 1. Geographic Distribution of Meningococcal Outbreaks, July 1, 1994 to June 30, 2002 
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Table I. Description of Outbreak-associated Cases by Serogroup 
Variable Serogroup Total 
c B y 
Age Group 
<I year 3 (38%) 5 (62%) 0 (0%) 8 
1-5 years 34 (69%) 13 (27%) 2 (4%) 49 
6-17 years 65 (72%) 22 (24%) 4(4%) 91 
18-24 years 38 (74%) 12 (24%) 1 (2%) 51 
25-39 years 12 (100%) 0 (0%) 0 (0%) 12 
40-64 years 7 (70%) 3 (30%) 0 (0%) 10 
65+ years 2 (10%) 2 (10%) 16 (80%) 20 
Gender ' 
Male 104 (78%) 24 (18%) 6(4%) 134 L 
Female 53 (58%) 26 (29%) 12 (13%) 91 
' 
Setting f= f 
Community 99 (76%) 27(21%) 4 (3%) 130 
Institution 64 (57%) 30 (26%) 19 (17%) 113 l 
l 
"' Clinical Presentation:j: • Meningitis 90 (75%) 24 (20%) 6 (5%) 120 I Meningococcemia 74 (60%) 30 (24%) 19 (16%) 123 t 
Pneumonia 0 (0%) 0 (0%) 11 (100%) 11 
Other 2 (50%) 2 (50%) 0 (0%) 4 
Deaths 34 (72%) 9 (19%) 4 (9%) 47 




Table 2. Characteristics of Outbreak-Associated Cases Compared to Sporadic 
Cases 
Variable No. of No. of Risk Ratio 95%CI 




c 163 (67.1) 583 (28.6) 2.3 2.1-2.6 
B 57 (23.4) 749 (36.7) 0.6 0.5-0.8 
y 23 (9.5) 663 (32.5) 0.3 0.2-0.4 
• 
W-135 0 (0) 44 (2.2) t t I 
Male Gender 135 (59.0) 1187 (50.5) 1.2 1.0-1.3 L 
Age Group 
<1 year 8 (3.2) 324 (13.8) 0.2 0.1-0.5 
l= 1-5 years 50 (20.2) 382 (16.3) 1.3 1.0-1.6 g-
6-17 years 91 (36.8) 462 (19.7) 1.9 1.6-2 .. 3 
18-24 years 53 (21.5) 286 (12.2) 1.8 1.4-2.3 
k 25-39 years 12 (4.9) 216 (9.2) 0.5 0.3-0.9 
40-64 years 11 (4.5) 370 (15.7) 0.3 0.2-0.5 I 
65+ years 20 (8.1) 306 (13.0) 0.6 0.4-1.0 ~ 
Clinical Presentation:j: 
Meningitis 122 (53.7) 1118 (47.6) 1.1 1.0-1.3 
Meningococcemia 126 (55.8) * t t 
Pneumonia 11 (5.1) 206 (9.2) 0.5 0.3-1.0 
Death 48 (21.1) 261 (11.3) 1.9 1.4-2.5 t ~ 
* Data are not available 
t Value cannot be calculated 
:j: Groups are not mutually exclusive and thus rates do not sum to 100% 
Table 3. Case-Fatality Rate of Outbreak-Associated Cases Compared to 
Sporadic Cases 
Variable Case- Case- Risk Ratio 95% CI 
Fatality Fatality (RR) 




c 22 13 1.7 1.2-2.4 
B 18 9 1.9 1.0-3.6 
y 22 11 2.0 0.8-4.8 
Age Group 
<1 year 17 7 2.5 0.4-15.9 
1-5 years 24 5 4.8 2.5-9.3 
6-17 years 20 9 2.2 1.3-3.6 • 
18-24 years 20 14 1.5 0.8-2.8 ~ 
~ 
25-39 years 20 14 1.4 0.4-5.1 
40-64 years 18 14 1.3 0.4-4.7 
65+ years 27 20 1.4 0.6-3.2 L 
I Clinical Syndrome:j: Meningitis 13 10 1.3 0.8-2.2 ,--
Meningococcemia 31 * t t 
Pneumonia 25 14 1.8 0.5-6.3 
* Data are not available 
t Value cannot be calculated 
:j: Groups are not mutually exclusive and thus rates do not sum to 1 00% 
Table 4. Progression of meningococcal disease outbreaks in the United States, July l, 1994-
June 30 2002 ' 
STATE SETTL'lG GROUP WEEKI WEEK2 WEEK3 WEEK4 WEEKS WEEK6-10 WEEK 11-15 WEEK 16-20 WEEK>20 
Alaska community b 1 1 l l 
California commllility b 1 1 1 2 
Florida community b 4 1 l 2 1 
Ge~~ci~ community b l 2 
Missouri community b 1 1 1 1 1 
Wisconsin community b 1 2 
Arkansas institution b 2 
California institution b 3 (l) 1 
Connecticut institution b 1 1 
Florida institution b 2 (!) 1 
Florida institution b 2 2 
Florida institution b 2 1 
Iowa institution b 1 1 
Kansas institution b 2 
New Hamnshire institution b 2 1 
North Carolina institution b 1 1 
Vermont institution b 2 
Vi;;iuia institution b 2 
Washimrton institution b 5 
California conununity c 1 3 2 
Connecticut community c 1 1 1 
Florida cormnunity c 2 2 1 
Florida community c 2 I' 
Florida community c 3 1 2 1 
Geo-;:;ia community c 1 3 
Illinois community c 4 ' 
Illinois connnunin. c 1 4' 
Iowa community c 1 2 
Kentucky community c 1 1 1 
Minnesota community c 6 1* l ' 
Minnesota community c 1 1 2 
Missouri community c 1 4(2) 1 
New Mexico community c 4 2' 1 
North Dakota community c 3(1) 
Texas community c 1 2 * 
Texas community c 2 1 2' 1 1 22 
Texas community c 1 3 ' 
Wisconsin community c 1 1 1 1 l 
California institution c 2 
California institution c 3 
California institution c 1 1 
Colorado institution c 2 
Maryland institution c 1 1' 
Maryland institution c 1 2(1) 
Massachusetts institution c 2 
MicbJ;an institution c 2 
Missouri institution c 2 
New Hamoshire institution c 2(1) 
New York institution c 2 
Ohio institution c 2 1 
Pennsylvania institution c 1 1 
Pennsylvania institution c 1 1 
Pennsylvania institution c 1 1 
South Carolina institution c 1 1 1 
Tennessee !institution c 1 2 
Tennessee institution c 2 
Texas institution c 1 1 2' 
Texas institution c 2 1 1 
Texas institution c I I I * 
Texas institution c 3(2) ' 
Texas institution c 2(1) ' 
Texas institution c 2 ' 1 
Virginia institution c 2 1 ' 
Virginia institution c 1 2 
Virginia institution c 3 
Washington institution c 1 1' 
Washington institution c 1 1 1 
Pennsylvania community y 2(1) 2(1) 
Arizona institution y 2 I ' 
Louisiana institution y 1 I 
Massachusetts institution y 2(1) 
New York institution y 1 I 
North Carolina institution y 2 
Ohio institution y 2 
Ohio institution y 
Virginia institution y I 1 
~ Imtlatwn ofvaccmatwn campmgn 
Red type indicates cases that resulted in death 
